7月7日，Apogee Therapeutics是一家临床阶段的生物技术公司，致力于推进优化的新型生物制品，具有在最大的炎症和免疫（I&I）市场中差异化疗效和给药的潜力，今天宣布了APG777的第II期APEX临床试验A部分的16周积极数据。这是一种潜在的最佳类抗IL-13抗体，用于中度至重度特应性皮炎（AD）患者。消息发布后，Apogee Therapeutics美股盘前一度飙涨逾50%。
7月7日，Apogee Therapeutics是一家临床阶段的生物技术公司，致力于推进优化的新型生物制品，具有在最大的炎症和免疫（I&I）市场中差异化疗效和给药的潜力，今天宣布了APG777的第II期APEX临床试验A部分的16周积极数据。这是一种潜在的最佳类抗IL-13抗体，用于中度至重度特应性皮炎（AD）患者。消息发布后，Apogee Therapeutics美股盘前一度飙涨逾50%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
